Photodynamic Therapy for the Treatment of Bowen's Disease: A Review on Efficacy, Non-Invasive Treatment Monitoring, Tolerability, and Cosmetic Outcome.

ALA-PDT Bowen’s disease MAL-PDT immunocompromised patients non-melanoma skin cancer photodynamic therapy squamous cell carcinoma in situ

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
03 Apr 2024
Historique:
received: 23 02 2024
revised: 28 03 2024
accepted: 30 03 2024
medline: 27 4 2024
pubmed: 27 4 2024
entrez: 27 4 2024
Statut: epublish

Résumé

Bowen's disease represents the in situ form of cutaneous squamous cell carcinoma; although it has an excellent prognosis, 3-5% of lesions progress to invasive cutaneous squamous cell carcinoma, with a higher risk in immunocompromised patients. Treatment is therefore always necessary, and conventional photodynamic therapy is a first-line option. The aim of this review is to provide an overview of the clinical response, recurrence rates, safety, and cosmetic outcome of photodynamic therapy in the treatment of Bowen's disease, considering different protocols in terms of photosensitizers, light source, and combination treatments. Photodynamic therapy is a valuable option for tumors at sites where wound healing is poor/delayed, in the case of multiple and/or large tumors, and where surgery would be difficult or invasive. Dermoscopy and reflectance confocal microscopy can be used as valuable tools for monitoring the therapeutic response. The treatment is generally well tolerated, with mild side effects, and is associated with a good/excellent cosmetic outcome. Periodic follow-up after photodynamic therapy is essential because of the risk of recurrence and progression to cSCC. As the incidence of keratinocyte tumors increases, the therapeutic space for photodynamic therapy will further increase.

Identifiants

pubmed: 38672152
pii: biomedicines12040795
doi: 10.3390/biomedicines12040795
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

Paolo Antonetti (P)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Cristina Pellegrini (C)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Chiara Caponio (C)

Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Manfredo Bruni (M)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Lorenzo Dragone (L)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Mirco Mastrangelo (M)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Maria Esposito (M)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Maria Concetta Fargnoli (MC)

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Dermatology Unit, Ospedale San Salvatore, 67100 L'Aquila, Italy.

Classifications MeSH